Krsnna Diagnostics IPO notes: 'Let's do Good' ❓

Hit the 'retweet' & help us educate more investors

A thread 🧵👇

#IPOwithJST
1/ Basics about the IPO

Issue Dates: 4 - 6 August
Issue Size: ₹ 1,211 Crore (400crs Fresh Issue & 811crs OFS)
Mcap at the upper band: 2994crs
Price Band: ₹ 933 - 954
Retail Quota: 10%

Promoter stake to go from 32% to 27% post IPO.
2/ About the company.

Krsnaa Diagnostics provides technology-enabled services such as imaging (including radiology), pathology/clinical laboratory, and teleradiology

to public and private hospitals, medical colleges and community health centres across India.
3/ They focus on the public-private partnership (“PPP”) diagnostics segment and have the largest presence in the diagnostic PPP segment.

Contracts are typical of long-term in nature.

Won 77.6% of all tenders since inception & have thus deployed 1823 diagnostic centers.
4/ Operational performance indicators
5/ Strengths

- Cost Competitive: Radiology tests are priced 45%-60% below market rates & pathology tests are 40%-80% below
- Extensive footprint & Infra: Among the few cos. in India to have MRI machines ranging from 0.2-3 Tesla machines & multi-slice CT to 128 slice CT scanners
6/

- High revenue visibility (Non-Covid rev) due to 2-10 year long govt. PPP contracts
- Experienced promoters & management team supported by a strong employee base
7/ Services they offer & the distribution.
8/ Objective of the issue

Plans to use Rs 150 crore to set up 29 diagnostic centres across multiple states.

It also plans to repay/ pre-pay debt worth Rs 146 crore to the lenders in FY22. The company’s total borrowings stood at Rs 231.7 crore as of March 2021.
9/ Financials

- Good Cashflow conversion (80%+ EBITDA)
- Capex heavy business, Working Capital under control
- Strong Margins at 25-30% & gross margins of 80-85%
- COVID benefited the revenues in FY21, Non-COVID rev back to pre-COVID
10/ Risks

- 70% of rev from government agencies: Could lead to payment delays
- Competitive tender bidding process to get in: cost competitiveness could be challenged by some new entrant
- Contracts are based on fixed price arrangements: margins are not under their control.
11/

- 70% of rev from 3 states; Maharashtra, Rajasthan & Karnataka.
- Delays in the establishment of diagnostic centres could lead to termination of the agreements or cost overruns.
- Failure to establish and comply with appropriate quality standards could result in litigations.
12/

At 8x EV/Sales, 32x EV/ EBITDA & more than 90 times earnings, plus the commoditized nature of the industry due to high competition & also the boost in sales from COVID-19, we would rather wait & watch this company face an increasing RM cost scenario.

• • •

Missing some Tweet in this thread? You can try to force a refresh
 

Keep Current with ᴀɴɪsʜ ᴍᴏᴏɴᴋᴀ

ᴀɴɪsʜ ᴍᴏᴏɴᴋᴀ Profile picture

Stay in touch and get notified when new unrolls are available from this author!

Read all threads

This Thread may be Removed Anytime!

PDF

Twitter may remove this content at anytime! Save it as PDF for later use!

Try unrolling a thread yourself!

how to unroll video
  1. Follow @ThreadReaderApp to mention us!

  2. From a Twitter thread mention us with a keyword "unroll"
@threadreaderapp unroll

Practice here first or read more on our help page!

More from @AnishA_Moonka

31 Jul
Windlas Biotech IPO notes 💊

'What's in a name? that which we call a rose by any other name would smell as sweet' ~Shakespeare

Hit the 'retweet' & help us educate more investors

A thread 🧵👇

#IPOwithJST
1/ Basics about the IPO 👇

Incorporated in 2001

Fresh Issue of 165crs (50 for capex | 48 for Working capital | 20 for debt payment) + OFS of 237crs (Partially by promoter & PE Tano selling out as the fund tenure is up)

~ Total raise of 402crs
2/ About the company (Not a Biotech company)

A Contract manufacturer for formulation cos. (204 in total) for Indian markets & a small domestic OTC biz

3279 products, 4 plants with 700cr tablets/capsules capacity

Emphasis on chronic (60% of rev) & complex generics (70% of rev)
Read 15 tweets
28 Jul
A thread on the snippets (paragraphs & quotes) from the book ‘Amazon Unbound: Jeff Bezos & the invention of a Global Empire 🏰’ by Brad Stone

This 🧵 will be updated as I read further & further. Image
1/ Quotes to ponder about 👇 Image
2/ The scar tissues. Image
Read 11 tweets
26 Jul
Glenmark Life Sciences (GLS) IPO notes 🔬

Plans to take the capacity to 1762KL (currently 762KL) in the next 4 years.

Hit the 'retweet' & help us educate more investors

A thread 🧵👇

#IPOwithJST
1/ About the company

Developer & manufacturer of high value, non- commoditized APIs (complex & low competition) in chronic therapeutic areas: CVS, CNS, pain management & diabetes, etc

Basic details about the IPO 👇

Note: After paying off liabilities, 150crs remain for capex.
2/ The Journey

Established the API business in FY02

Since 2015, Have not received any adverse reactions from regulators (USFDA, PMDA) in the total 38 audits & inspections & Have gone through 432 customer audits.

Filled 403 DMFs & CEP registration across markets globally.
Read 18 tweets
17 Jul
A thread on the snippets (paragraphs & quotes) from the book ‘The Hidden Life Of Trees: What They Feel, How They Communicate’ by Peter Wolleben (A forester 🌳)

‘Trees in the forest are social beings.’

This thread will be updated as I read further & further.
1/ Trees are underrated.
2/ Wood Wide Web.
Read 22 tweets
15 Jul
Mr. NS Mohan (MD, Suprajit Engineering) gives a perfect example to explain the Indian Automotive Industry: The doll 'Okiagari- Koboshi'

Whenever something hits them, they upright themselves & then again something hits them & on & on. (1/3) Image
Alludes to the fact that been in the industry since 1985 & never seen them being hit with such severity & regularity.

Still, the industry isn't out.

These are the trends that are playing out 👇 (2/30 Image
So what lies ahead? He said: I don't know. (3/3) Image
Read 4 tweets
8 Jul
A thread on the snippets (paragraphs & quotes) from the book ‘Modern Monopolies: What it Takes to Dominate the 21st-Century Economy’

This thread will be updated as I read further & further.
1/ The burning platform.
2/ Why did Nokia fail?
Read 15 tweets

Did Thread Reader help you today?

Support us! We are indie developers!


This site is made by just two indie developers on a laptop doing marketing, support and development! Read more about the story.

Become a Premium Member ($3/month or $30/year) and get exclusive features!

Become Premium

Too expensive? Make a small donation by buying us coffee ($5) or help with server cost ($10)

Donate via Paypal Become our Patreon

Thank you for your support!

Follow Us on Twitter!

:(